The SWOG Statistical and Data Management Center (SDMC) plays a vital role in SWOG's overall mission to direct and participate in clinical trials tht will lead to effective treatment and prevention of cancer and to improve quality of life for cancer patients and survivors. The SDMC provides statistical leadership and data management expertise in the design, implementation, monitoring, analysis and interpretation of clinical trials and translational medicine studies. Key SDMC goals include the following: a) to design and implement statistically rigorous and efficient clinical trials;b) to carefully monitor ongoing trils and use state-of-the-art statistical analysis methods to analyze and interpret study results;c) to conduct statistical methods research in clinical trial design and analysis, and the analysis of translational medicine studies;d) to develop systems and utilize technologies for high quality and timely collection, review, storage and retrieval of clinical and biologic data;e) to educate SWOG investigators and other oncology research professionals in leading edge scientific design, statistical techniques and data management methods;f) to evaluate novel strategies for the efficient collection of specific types of patient data including electronic medical record (EMR and web-based methods;and g) to be a dynamic member of the NCTN by providing a wealth of experience and leadership for NCTN endeavors such as steering committees and working groups. The SWOG SDMC contributes meaningfully to the goals of SWOG within the NCTN to provide generalizable, high quality and efficient strategies that can be used by other clinical trials organizations and researchers in the conduct of oncology clinical trials and analysis of associated biologic studies.
Well designed and conducted clinical trials are the primary means for improving therapy for cancer, advancing the chance for cure and increasing the length and quality of life of patients. The SWOG SDMC aims to be a leader in the field through efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials have the greatest potential impact on cancer patients.
|Walter, R B; Othus, M; Burnett, A K et al. (2015) Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29:312-20|
|Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41|
|Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40|
|Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62|
|Hills, Robert K; Castaigne, Sylvie; Appelbaum, Frederick R et al. (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986-96|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
|Dias, M M; Pignon, J-P; Karapetis, C S et al. (2014) The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J 14:424-31|
|Unger, Joseph M; Barlow, William E; Martin, Diane P et al. (2014) Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 106:dju002|
|Ostronoff, Fabiana; Othus, Megan; Gerbing, Robert B et al. (2014) NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood 124:2400-7|
|Twardowski, Przemyslaw W; Mack, Philip C; Lara Jr, Primo N (2014) Papillary renal cell carcinoma: current progress and future directions. Clin Genitourin Cancer 12:74-9|
Showing the most recent 10 out of 19 publications